Tetraphase surges on positive antibiotic readout; AstraZeneca forges cancer R&D deal with RedX;

@FierceBiotech: $RHHBY CEO Schwan took a hands-on approach negotiating $8.3B $ITMN buyout. Report | Follow @FierceBiotech

@JohnCFierce: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Story | Follow @JohnCFierce

@DamianFierce: Steven Paul (former $LLY exec, $SAGE co-founder) takes the helm at Third Rock's Voyager Therapeutics. Release (PDF) | Follow @DamianFierce

@EmilyMFierce: Ebola treatments caught in limbo. More from Nature | Follow @EmilyMFierce

> Watertown, MA-based Tetraphase Pharmaceuticals ($TTPH) got a boost from news that the lead-in work for its late-stage program for eravacycline, an antibiotic for urinary tract infections, proved positive. The treatment "compared favorably to levofloxacin," sending shares up about 15% Wednesday morning. Release

> Amgen submitted the oncolytic cancer vaccine talimogene laherparepvec (T-Vec) to the EMA. The big biotech simultaneously submitted its PCSK9 cholesterol treatment evolocumab. Release/Release

> AstraZeneca ($AZN) inked a discovery and development deal with RedX, which is moving in to some of the pharma giant's vacated space in Alderley Park in the UK. They'll be working on molecules that can influence tumor growth and survival. Story

> Cambridge, MA-based Epizyme says that its president and CFO, Jason Rhodes, has resigned with plans to take a new job at a venture capital company. Release

Medical Device News

@FierceMedDev: ICYMI: ArthroCare $750M fraud saga culminates in decades-long prison term. Article | Follow @FierceMedDev

@VarunSaxena2: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Bionic eye bridges gap between visual signals and brain, gives blind patients a chance to see. More from The Atlantic | Follow @EmilyWFierce

> FDA clears wireless, vitals monitor patch that transmits to smartphone. Story

> J&J shoring up for latest courtroom battle over all-metal hip implant. Article

Pharma News

@FiercePharma: Tops in FiercePharmaManufacturing Tues: Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant. Article | Follow @FiercePharma

@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Teva trounces patent on AstraZeneca's Symbicort, opening up U.K. copycat launch. Story | Follow @CarlyHFierce

> AstraZeneca's Soriot brushes off chatter about new Pfizer bid. Story

> Forest plan to force Alzheimer's patients to new drug tripped up by supply issues. Article

Drug Delivery News

> UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. More

> RNAi pipeline active as investors, patients wait for commercialization. Item

> BioTime enters academic collaborations to advance its hydrogel for vocal fold scarring. Article

> Artificial virus promises effective drug delivery and gene therapy. Story

> Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone? Report

Diagnostics News

> Companion diagnostics crossed the billion-dollar threshold in 2013: Report. More

> Finnish gene sequencing Dx startup wins funding to back U.S. expansion. Report

> Quest scientists and others identify new rheumatoid arthritis biomarker. Item

> NanoString mourns the sudden death of its CMO. Story

> MIT discovers malaria parasitic waste has Dx biomarker potential. Article

Pharma Marketing News

> J&J, Bayer look to turbocharge Xarelto with new label-expanding studies. More

> Genzyme puts $310,250 price tag on new Gaucher-fighting pill. Article

> Actavis' Namenda switch exceeds expectations, and its ability to supply new version. Item

> GSK can't deep-clean its image overnight. But it can revamp its websites. Story

> Novartis sees 'most exciting launch' ever with megablockbuster-to-be heart drug. Report